Cover2 Resources

In our three-part series with American Overdose author, Chris McGreal, we took an in-depth look at some of the policies and practices of the FDA that helped lead to our nation’s worst health crisis in history. During the series, I spoke with the former chair of the FDA advisory committee, who’s role is to review and advise on drugs under consideration for approval by the FDA. I was surprised by his responses to my questions, rejecting the notion that mistakes were made, despite the number of deaths the opioids approved during his tenure caused. My take away from this interview was that the FDA is stuck in an inflexible mindset, and has made no attempt to rectify the impact the opioid crisis has had on our country over the last twenty years. Unsettled, I decided to dig a little deeper to find out if my impressions were representative of the today’s FDA. To help me answer that question is Dr. Raeford Brown, who for the last five years has been the chair of the FDA’s anesthetic and analgesic drug products advi